Bacteroides fragilis
Classification
Kingdom: Bacteria
Phylum: Bacteroidetes
Class: Bacteroidia
Order: Bacteroidales
Family: Bacteroidaceae
Genus: Bacteroides
Species: Bacteroides fragilis
Introduction
Bacteroides fragilis is an anaerobic, non-spore-forming, Gram-negative, rod-shaped bacterium found in the human colon.[1] Although it is relatively rare compared to other species of Bacteroides, it is the most common clinical isolate of its genus.[2] Enterotoxigenic B. fragilis (ETBF) is responsible for a large number of opportunistic infections in hospitals and contributes significantly to morbidity and mortality; in addition, ETBF is known to cause serious complications such as colorectal cancer and colitis.[3] Although B. fragilis has traditionally been investigated as a common infectious disease, there is mounting evidence that nontoxic B. fragilis (NTBF) plays an important beneficial role in the human microbiome. This bacterium is of interest to researchers because of its ability to evade immune responses and its evolving drug resistance, as well as the beneficial effects some strains may have.
Genetics
Diagnosis with ETBF is confirmed by using PCR to determine the presence of genes coding for B. fragilis toxins.[4] A single stretch of DNA approximately 6,000 base pairs long distinguishes enterotoxic from nontoxic strains of B. fragilis.[5] This 6-kb region contains not only the bft gene, but also a 700-bp series of promotors. There are no fewer than three variants of the bft gene that codes for these toxins. These three gene variants are nearly identical; two of the genes, BFT-1 and BFT-2, are 95% similar.[6] BFT-3 is more than 90% similar to BFT-1, and 96% identical to BFT-2.[7] Despite the extreme similarity between these three gene variants, together they may code for as many as 25 different amino acid changes in the final protein.
In addition, sequencing the genome of one strain B. fragilis has revealed numerous stretches of inverted DNA, creating a vast array of potential configurations of the outer membrane including eight different polysaccharides.[8] This extensive diversity allows B. fragilis as a species to evade attempts by the immune system to recognize and destroy it.
Microbiome
Enterotoxic Strains
BF toxin causes dramatic inflammation and "loss of cell-to-cell attachments" which causes characteristic abdominal pain and diarrhea.[9] The toxin works by cleaving E-cadherin[10], which regulates HT29/C1 cell growth in the colon.[11] ETBF also upregulates the antiapoptotic protein cIAP2.[12] Finally, ETBF releases several proinflammatory chemokines.[13] The cumulative result is that cells in the colon proliferate more rapidly, become isolated and inflamed, and become resistant to programmed cell death, increasing the risk of cancer and causing painful diarrhea.
Nontoxic Strains
Some strains of B. fragilis are nontoxic and even beneficial to their host organism. In germ-free mice, colonization with B. fragilis restores the activity of CD4+ T cells [14] A single molecule produced by NTBF, polysaccharide A (PSA), has been shown to protect against colitis by upregulating production of interleukin-10, a powerful anti-inflammatory cytokine. In germ-free animals with poorly-functioning immune systems, NTBF colonization dramatically improved spleen morphology, indicating that PSA may play a role in lymphocyte development.[15]
In addition to improving immune function, B. fragilis may have an effect on behavioral health. In a mouse model for Autism Spectrum Disorder (ASD), colonization with NTBF reduced or eliminated abnormalities in the expression of multiple genes and "correct[ed] intestinal permeability" in the colon.[16] The same study showed that NTBF colonization may have also served as a treatment for various behavioral symptoms associated with ASD, such as anxiety, repetitive behaviors, and inability or refusal to communicate. All of these improvements occurred even when the mice were colonized with a PSA-deficient strain of B. fragilis.
References
- ↑ Kuwahara, T., A. Yamashita, H. Hirakawa, H. Nakayama, H. Toh, N. Okada, S. Kuhara, M. Hattori, T. Hayashi, and Y. Ohnishi. 2004. Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation. Proc. Natl. Acad. Sci. USA 101:14919-14924.
- ↑ Salyers, A. A. 1984. Bacteroides of the human lower intestinal tract. Annu. Rev. Microbiol. 38:293-313.
- ↑ Redondo, M. C., M. D. Arbo, J. Grindlinger, and D. R. Snydman. 1995. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin. Infect. Dis. 20:1492-1496.
- ↑ Sears, Cynthia L. "Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes." Clinical microbiology reviews 22.2 (2009): 349-369.
- ↑ Moncrief, J. S., A. J. Duncan, R. L. Wright, L. A. Barroso, and T. D. Wilkins. 1998. Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis. Infect. Immun. 66:1735-1739.
- ↑ Franco, A. A., L. M. Mundy, M. Trucksis, S. Wu, J. B. Kaper, and C. L. Sears. 1997. Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect. Immun. 65:1007-1013.
- ↑ Chung, G. T., A. A. Franco, S. Wu, G. E. Rhie, R. Cheng, H. B. Oh, and C. L. Sears. 1999. Identification of a third metalloprotease toxin gene in extraintestinal isolates of Bacteroides fragilis. Infect. Immun. 67:4945-4949.
- ↑ Kuwahara, T., A. Yamashita, H. Hirakawa, H. Nakayama, H. Toh, N. Okada, S. Kuhara, M. Hattori, T. Hayashi, and Y. Ohnishi. 2004. Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation. Proc. Natl. Acad. Sci. USA 101:14919-14924.
- ↑ Weikel, C. S., F. D. Grieco, J. Reuben, L. L. Myers, and R. B. Sack. 1992. Human colonic epithelial cells, HT29/C1, treated with crude Bacteroides fragilis enterotoxin dramatically alter their morphology. Infect. Immun. 60:321-327.
- ↑ Wu, S., K. J. Rhee, M. Zhang, A. Franco, and C. L. Sears. 2007. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage. J. Cell Sci. 120:1944-1952.
- ↑ Wu, S., P. J. Morin, D. Maouyo, and C. L. Sears. 2003. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 124:392-400.
- ↑ Kim, J. M., J. Y. Lee, and Y. J. Kim. 2008. Inhibition of apoptosis in Bacteroides fragilis enterotoxin-stimulated intestinal epithelial cells through the induction of c-IAP-2. Eur. J. Immunol. 38:2190-2199.
- ↑ Sears, C. L., S. Islam, A. Saha, M. Arjumand, N. H. Alam, A. S. G. Faruque, M. A. Salam, J. Shin, D. Hecht, A. Weintraub, R. B. Sack, and F. Qadri. 2008. Enterotoxigenic Bacteroides fragilis infection is associated with inflammatory diarrhea. Clin. Infect. Dis. 47:797-803.
- ↑ Mazmanian, S. K., J. L. Round, and D. L. Kasper. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620-625.
- ↑ Mazmanian, S. K., C. H. Liu, A. O. Tzianabos, and D. L. Kasper. 2005. An Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune System. Cell 122.1 (2005): 107-118.
- ↑ Hsaio, E. Y., S. W. McBride, S. Hsien, G. Sharon, E. R. Hyde, T. McCue, J. A. Codelli, J. Chow, S. E. Reisman, J. F. Petrosino, P. H. Patterson, and S. K. Mazmanian. 2013. Microbiota Modulate Behavioral and Physiological Abnormalities Associated with Neurodevelopmental Disorders. Cell 155.7 (2013): 1451-1463.
Edited by James Cawthon, student of Joan Slonczewski for BIOL 116 Information in Living Systems, 2019, Kenyon College.